Bimekizumab

• CAT Number: I042427
• CAS Number: 1418205-77-2
• Purity: ≥95%

Bimekizumab (Cat No.: I042427) is a humanized monoclonal antibody that selectively inhibits interleukin-17A (IL-17A) and interleukin-17F (IL-17F), key cytokines involved in inflammatory pathways. It is approved for the treatment of moderate to severe plaque psoriasis and is under investigation for other inflammatory diseases like psoriatic arthritis and ankylosing spondylitis. By dual targeting IL-17A and IL-17F, Bimekizumab offers enhanced suppression of inflammation, leading to improved clinical outcomes. It represents a next-generation biologic therapy for autoimmune and chronic inflammatory disorders.

Reference

[1]. Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.
[Content Brief]